Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

103
10° CONGRESSO NAZIONALE SIMIT
Abstract 251
- MONOTHERAPY WITH ATAZANAVIR AS A SIMPLIFICATION STRATEGY:
RESULTS FROM AN OBSERVATIONAL STUDY. -
Cossarini F.* [1] , Salpietro S. [1] , Galli L. [1] , Gianotti N. [1] , Nozza S. [1] , Soagnuolo V. [1] , Hasson H. [1] , Bossolasco
S. [1] , Pizzocolo C. [1] , Lazzarin A. [1] , Tambussi G. [1] , Castagna A. [1]
- [1] San Raffaele Scientific Institute ~ Milano
INFEZIONI DA HIV
Premessa: Protease Inhibitors (PI) monotherapy is an appealing treatment simplification
strategy for many HIV-infected patients. Atazanavir has not been studied as extensively as
other PIs for monotherpy treatment.
Obiettivo: Aim of the study was to describe the immunovirological response to atazanavir
monotherapy (ATV/r 300/100 mg or ATV 400 mg). We studied HIV-infected individuals
followed at our Clinic who switched from a HAART regimen to either a ATV/r or an ATV
monotherapy while virologically suppressed (HIV-RNA50 copies/mL; and the
immunological variation defined as CD4+ and CD8+ change from the start of atazanavir
monotherapy. Results are expressed as median (IQR) or n(%).
Risultati: 43 subjects were included: ATV/r or ATV were prescribed in 30(68%) and
13(30%) patients, respectively. Patients switched to monotherapy due to toxicity [23(53%)]
or treatment simplification [18 (47%)]. Twenty-four (56%) patients were on a PI regimen
[17 (40%) on atazanavir] before monotherapy. After a median of 10.0 (5.4-23.4) months of
follow-up, 3(7%) subjects experienced virological failure. CD4+ change was -9(-
79/+75)cells/mcl; CD4% change was 1.7(-2.7/+4.4), CD8+ change was -157(-
360/+cells/mcl and CD8% change was -6(-7.4/-1). Additional patients characteristics and
results are in Table-1.
Conclusione: We observed a very low proportion of virological failure on atazanavir
monotherpy, with stable CD4+ counts and a reduction in CD8+ counts. Although the small
sample size and the retrospective nature of this study, our
results may support a potential role for atazanavir in PI monotherapy simplification
strategies and encourage further studies on this topic.